- H.R. 10171August 27, 2026
- H.R. 10156August 27, 2026
- H.R. 10172August 27, 2026
- H.R. 10160August 27, 2026
- H.R. 10181August 27, 2026
- H.R. 10176August 27, 2026
- H.Res. 1496August 27, 2026
- H.R. 10164August 27, 2026
- H.R. 10170August 27, 2026
- H.Res. 1494August 27, 2026
- H.R. 10163August 27, 2026
- H.R. 10157August 27, 2026
- Administration
- Agriculture
- Agriculture, Nutrition, And Forestry
- Appropriations
- Armed Services
- Banking, Housing, And Urban Affairs
- Budget
- Commerce, Science, And Transportation
- Education and Workforce
- Energy And Commerce
- Energy And Natural Resources
- Environment And Public Works
- Ethics
- Finance
- Financial Services
- Foreign Affairs
- Foreign Relations
- Health, Education, Labor, And Pensions
- Homeland Security
- Homeland Security And Governmental Affa…
- Indian Affairs
- Indian and Insular Affairs
- Intelligence
- Judiciary
- Natural Resources
- Oversight And Government Reform
- Permanent Select Intelligence
- Rules
- Rules And Administration
- Science, Space, And Technology
- Select Intelligence
- Small Business
- Small Business And Entrepreneurship
- Subcommittee on Aviation
- Subcommittee on Border Security and Enf…
- Subcommittee on Coast Guard and Maritim…
- Subcommittee on Commodity Markets, Digi…
- Subcommittee on Conservation, Research,…
- Subcommittee on Counterterrorism and In…
- Subcommittee on Cybersecurity and Infra…
- Subcommittee on Disability Assistance a…
- Subcommittee on Economic Development, P…
- Subcommittee on Economic Opportunity
- Subcommittee on Emergency Management an…
- Subcommittee on Energy and Mineral Reso…
- Subcommittee on Federal Lands
- Subcommittee on Forestry and Horticultu…
- Subcommittee on General Farm Commoditie…
- Subcommittee on Health
- Subcommittee on Highways and Transit
- Subcommittee on Livestock, Dairy, and P…
- Subcommittee on Nutrition and Foreign A…
- Subcommittee on Oversight and Investiga…
- Subcommittee on Oversight, Investigatio…
- Subcommittee on Railroads, Pipelines, a…
- Subcommittee on Transportation and Mari…
- Subcommittee on Water Resources and Env…
- Subcommittee on Water, Wildlife and Fis…
- Transportation And Infrastructure
- Veterans' Affairs
- Ways And Means

S. 1862
U.S. Senate•In Senate Committee
Summary
S. 1862, the ORPHAN Cures Act, was introduced in the Senate on May 22, 2025 by Sen. John Barrasso (R) with 1 co-sponsor. It was referred to Finance, and last saw action on May 22, 2025: Read twice and referred to the Committee on Finance. (text: CR S3119).
Record
Text
S. 1862 has 1 co-sponsor.
sb1862/introduced-in-senate.txt119 S1862 IS: Optimizing Research Progress Hope And New Cures ActU.S. Senate2025-05-22text/xmlENPursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.II119th CONGRESS1st SessionS. 1862IN THE SENATE OF THE UNITED STATESMay 22, 2025Mr. Barrasso (for himself and Mr. Heinrich ) introduced the following bill; whichwas read twice and referred to the Committeeon FinanceA BILLTo amend title XI of the Social Security Act to expand and clarify theexclusion for orphan drugs under the Drug Price Negotiation Program.1.Short titleThis Act may be cited as the Optimizing Research Progress Hope And New Cures Act or the ORPHAN Cures Act .2.Expanding and clarifying the exclusion for orphan drugs under the Drug PriceNegotiation ProgramSection 1192(e) of the Social Security Act ( 42 U.S.C. 1320f–1(e) ) is amended—(1)in paragraph (1), by adding at the end the following new subparagraph:(C)Treatment of former orphan drugsIn calculating the amount of time that has elapsed with respect to the approval of a drug or licensure of a biological product under subparagraph (A)(ii) and subparagraph (B)(ii), respectively, the Secretary shall not take into account any period during which such drug or product was a drug described in paragraph (3)(A).; and(2)in paragraph (3)(A)—(A)by striking only one rare disease or condition and inserting one or more rare diseases or conditions ; and(B)by striking such disease or condition and inserting one or more rare diseases or conditions (as such term is defined in section 526(a)(2) of the Federal Food, Drug, and Cosmetic Act) .
Tracker
The tracker indicates the progress of this legislation as it moves through the legislative process.
- Introduced2025-05-22
- Passed Senate
- Passed House
- Conference
- To President
- Became Law
CRS Summary
The summaries are the Congressional Research Service’s, one per stage. Read them in full.
Introduced in Senate May 22, 2025
sb1862/introduced-in-senate.mdShown Here:
Introduced in Senate (05/22/2025)
Sponsors
Sen. John Barrasso (R) sponsors S. 1862, and 1 member has co-sponsored it from the day it was introduced.
Committees
S. 1862 went before 1 committee: Finance.
Actions
S. 1862 has taken 2 actions since May 22, 2025.
| Chamber | Action | |||
|---|---|---|---|---|
May 22, 2025 | Senate | Read twice and referred to the Committee on Finance. (text: CR S3119)Finance Committee | ||
May 22, 2025 | — | Introduced in Senate |
Votes
S. 1862 has not gone to a roll call.
Related bills
1 bill is related to S. 1862.
Titles
S. 1862 goes by 4 titles, 2 of them short titles.
- ORPHAN Cures Act — Display Title
- ORPHAN Cures Act — Short Title(s) as Introduced
- Optimizing Research Progress Hope And New Cures Act — Short Title(s) as Introduced
- A bill to amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program. — Official Title as Introduced
Lobbying
28 clients hired 19 firms and 103 registered lobbyists who named S. 1862 in 96 quarterly filings, 2025 to 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.
Filed under Medicare/Medicaid, Health Issues, Taxation/Internal Revenue Code, Copyright/Patent/Trademark, Pharmacy, Trade (domestic/foreign), Budget/Appropriations, Defense.
Clients
Who paid to be heard, by how many filings named the bill. The 20 that filed most often, of 28.
| Client | Business | State | Firms | Filings | Reported |
|---|---|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | Pharmaceutical manufacturer. | Massachusetts | 3 | 13 | $750K |
| INCYTE CORPORATION | Biopharmaceutical company. | Delaware | 3 | 10 | $380K |
| IONIS PHARMACEUTICALS, INC. | Biotechnology company. | California | 2 | 8 | $200K |
| JOHNSON & JOHNSON SERVICES, INC. | Healthcare company. | District of Columbia | 2 | 5 | $250K |
| YC CONSULTING, LLC ON BEHALF OF PATIENTS RISING NOW | Government affairs and strategic advisory services firm | District of Columbia | 2 | 5 | $30K |
| EMD SERONO INC | — | District of Columbia | 1 | 5 | — |
| TRAVERE THERAPEUTICS | Biopharmaceuticals | California | 1 | 5 | — |
| ASTRAZENECA | — | — | 1 | 4 | $350K |
| BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.) | Biopharmaceutical company. | Massachusetts | 1 | 4 | $280K |
| EMD SERONO, INC. | Biopharmaceuticals. | Massachusetts | 1 | 4 | $200K |
| MERCK & CO. INC. | Manufacturer of pharmaceuticals | District of Columbia | 2 | 4 | $200K |
| BOEHRINGER INGELHEIM USA CORPORATION | Lobbyists | District of Columbia | 1 | 4 | — |
| LUNDBECK LLC | — | District of Columbia | 1 | 4 | — |
| AMGEN | Biotechnology. | California | 1 | 2 | $120K |
| ASTELLAS PHARMA US, INC. | Pharmacuetical company. | District of Columbia | 1 | 2 | $120K |
| UCB, INC. | Biopharmaceutical company | Georgia | 1 | 2 | $120K |
| DAIICHI SANKYO, INC. | Global pharmaceutical company. | New Jersey | 1 | 2 | $100K |
| JAZZ PHARMACEUTICALS, INC. | Specialty pharmaceuticals | California | 1 | 2 | $100K |
| STEALTH BIOTHERAPEUTICS INC. | Developing therapies to treat mitochondrial dysfunction. | Massachusetts | 1 | 2 | — |
| VERTEX PHARMACEUTICALS INCORPORATED | Biopharmaceutical company | Massachusetts | 1 | 1 | $60K |
Firms
Registrants who filed on the bill, by filings.
Lobbyists
Named on the filings that cite the bill. The 20 named most often, of 103.
| Lobbyist | Firms | Clients | Filings |
|---|---|---|---|
| COREY MALMGREN | 1 | 7 | 25 |
| JONATHON JONES | 1 | 6 | 20 |
| DANIEL ZAWITOSKI | 1 | 4 | 13 |
| JOHN TWOMEY | 1 | 3 | 13 |
| JOHN GONZALEZ | 1 | 3 | 11 |
| ALANNA TEMME | 1 | 2 | 10 |
| SONIA GOH | 1 | 2 | 10 |
| BRETT BAKER | 1 | 4 | 9 |
| GREG D'ANGELO | 1 | 4 | 9 |
| MARY SAVARY TAYLOR | 1 | 4 | 9 |
| RACHEL JONES HENSLER | 1 | 4 | 9 |
| AMY JENSEN | 1 | 3 | 7 |
| MATTHEW FUENTES | 1 | 6 | 7 |
| SARAH EGGE | 1 | 3 | 7 |
| TRACY SPICER | 1 | 6 | 7 |
| CHRISTOPHER PORTER | 1 | 1 | 5 |
| DAVID NICHOLS | 1 | 1 | 5 |
| JENNIFER BARBLAN | 1 | 1 | 5 |
| MALLORI MERANDINO | 1 | 1 | 5 |
| MELISSA BANASHAK | 1 | 1 | 5 |
Filings
The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.
| Client | Registrant | Period | Reported | Document |
|---|---|---|---|---|
| AARP | AARP | 2025 second_quarter | $5.1M | 2nd Quarter - Report |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | BIOTECHNOLOGY INNOVATION ORGANIZATION | 2025 fourth_quarter | $1.5M | 4th Quarter - Report |
| BOEHRINGER INGELHEIM USA CORPORATION | BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC | 2026 first_quarter | $1.2M | 1st Quarter - Report |
| EMD SERONO INC | EMD SERONO, INC. | 2025 second_quarter | $910K | 2nd Quarter - Report |
| EMD SERONO INC | EMD SERONO, INC. | 2026 first_quarter | $820K | 1st Quarter - Report |
| INCYTE CORPORATION | INCYTE CORPORATION | 2026 second_quarter | $750K | 2nd Quarter - Report |
| BOEHRINGER INGELHEIM USA CORPORATION | BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC | 2026 second_quarter | $710K | 2nd Quarter - Report |
| EMD SERONO INC | EMD SERONO, INC. | 2026 second_quarter | $700K | 2nd Quarter - Report |
| EMD SERONO INC | EMD SERONO, INC. | 2025 third_quarter | $700K | 3rd Quarter - Report |
| EMD SERONO INC | EMD SERONO, INC. | 2025 fourth_quarter | $670K | 4th Quarter - Report |
| BOEHRINGER INGELHEIM USA CORPORATION | BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC | 2025 fourth_quarter | $610K | 4th Quarter - Amendme… |
| BOEHRINGER INGELHEIM USA CORPORATION | BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC | 2025 fourth_quarter | $580K | 4th Quarter - Report |
| INCYTE CORPORATION | INCYTE CORPORATION | 2025 fourth_quarter | $530K | 4th Quarter - Report |
| INCYTE CORPORATION | INCYTE CORPORATION | 2025 second_quarter | $520K | 2nd Quarter - Report |
| INCYTE CORPORATION | INCYTE CORPORATION | 2026 first_quarter | $480K | 1st Quarter - Report |
| INCYTE CORPORATION | INCYTE CORPORATION | 2025 third_quarter | $330K | 3rd Quarter - Report |
| BIOMARIN PHARMACEUTICAL INC. | BIOMARIN PHARMACEUTICAL INC. | 2025 second_quarter | $270K | 2nd Quarter - Report |
| TRAVERE THERAPEUTICS | TRAVERE THERAPEUTICS | 2025 fourth_quarter | $260K | 4th Quarter - Report |
| TRAVERE THERAPEUTICS | TRAVERE THERAPEUTICS | 2026 first_quarter | $200K | 1st Quarter - Report |
| TRAVERE THERAPEUTICS | TRAVERE THERAPEUTICS | 2025 second_quarter | $200K | 2nd Quarter - Report |
Classification
The Congressional Research Service files S. 1862 under Health, one of its 31 policy areas.
CRS Subjects
CRS assigns every bill one policy area from its 31; S. 1862’s is Health.
s1862/policy-areas.txtSource: congress.gov · legiscan.com
